Search Within

Genitourinary Oncology Service

  1. "Irina Ostrovnaya"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (63)
Groups
  1. Biostatistics Service (128)
  2. Department of Medicine (128)
  3. Epidemiology and Biostatistics (128)
  4. Solid Tumor Oncology Division (128)
  5. Surgery (83)
  6. GSK Faculty (82)

More Groups

People
  1. Irina Ostrovnaya (128)
  2. Dean Bajorin (88)
  3. Gopakumar Iyer (72)
  4. Jonathan Rosenberg (69)
  5. Hikmat Al-Ahmadie (59)
  6. David Solit (55)

More People

Years
  1. 2025 (7)
  2. 2024 (11)
  3. 2023 (4)
  4. 2022 (13)
  5. 2021 (4)
  6. 2020 (11)

More Years

Publications
  1. Journal of Clinical Oncology (62)
  2. European Urology (7)
  3. Clinical Cancer Research (6)
  4. Cancer Discovery (5)
  5. Cancer (4)
  6. Cancer Research (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (64)
  2. American Association for Cancer Research (15)
  3. Elsevier Science, Inc. (9)
  4. Elsevier Inc. (8)
  5. Wiley Blackwell (8)
  6. Nature Publishing Group (6)

More Publishers

Results (128)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma
    Journal Article

    Chu, C. E.; Chen, Z.; Whiting, K.; Ostrovnaya, I.; Lenis, A. T.; Clinton, T. N.; Rammal, R.; Ozcan, G. G.; Akbulut, D.; Basar, M.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
    Journal Article

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies
    Journal Article

    Arora, K.; Suehnholz, S. P.; Zhang, H.; Ostrovnaya, I.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Brannon, A. R.; Bandlamudi, C.; Ladanyi, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Transcriptional analysis of bladder cancer histologic subtypes reveals novel drug target heterogeneity
    Meeting Abstract

    Tallman, J. E.; Kuo, F.; Koll, F.; Alam, S. M.; Basar, M.; Luo, J.; Gao, S. P.; Tang, X.; Yol, C.; Gokturk, G.; more...
    Urologic Oncology: Seminars and Original Investigations (2025)

    Fulltext@MSK | Save
  • Sample site impacts RNA biomarkers for renal cell carcinoma
    Journal Article

    Eismann, L.; Xie, A. X.; Tang, C.; Knezevic, A.; Ostrovnaya, I.; Kuo, F.; Ari Hakimi, A.; Reznik, E.; Kotecha, R. R.
    European Urology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save